Stay updated on Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:22:45.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a significant update in the phase II study of Cabozantinib in patients with RET fusion-positive advanced non-small cell lung cancer and other genotypes like ROS1 or NTRK fusions or increased MET or AXL activity. This change reflects a potential shift in the effectiveness or side effects of the medication being studied in treating specific types of cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:59.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for study participation.
    Difference
    52%
    Check dated 2024-05-22T20:53:25.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:15:53.000Z thumbnail image

Stay in the know with updates to Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.